RET (V778I)
Sign in to save this workspaceRET · Variant type: point · HGVS: p.V778I
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Tivozanib | 100.0% | 0.0% | 92.42 |
| 2 | Selpercatinib | 100.0% | 0.0% | 96.72 |
| 3 | Entrectinib | 100.0% | 0.0% | 93.69 |
| 4 | Pralsetinib | 100.0% | 0.0% | 93.43 |
| 5 | Alpelisib | 99.9% | 0.1% | 97.22 |
| 6 | Fedratinib | 99.9% | 0.1% | 96.21 |
| 7 | Nintedanib | 99.8% | 0.2% | 90.23 |
| 8 | Alectinib | 99.5% | 0.5% | 95.49 |
| 9 | Ponatinib | 99.4% | 0.6% | 78.23 |
| 10 | Lenvatinib | 99.3% | 0.8% | 97.74 |
| 11 | Gilteritinib | 98.8% | 1.1% | 88.97 |
| 12 | Tenalisib | 98.8% | 1.2% | 97.98 |
| 13 | Sorafenib | 97.9% | 2.1% | 96.72 |
| 14 | Sunitinib | 97.4% | 2.6% | 91.73 |
| 15 | Vandetanib | 97.3% | 2.7% | 95.74 |
| 16 | Repotrectinib | 97.0% | 3.0% | 84.21 |
| 17 | Brigatinib | 96.4% | 3.6% | 82.96 |
| 18 | Regorafenib | 96.3% | 3.7% | 95.99 |
| 19 | Futibatinib | 95.9% | 4.1% | 98.48 |
| 20 | Cabozantinib | 95.2% | 4.8% | 92.73 |
| 21 | Avapritinib | 93.6% | 6.4% | 97.73 |
| 22 | Erdafitinib | 93.0% | 7.0% | 95.71 |
| 23 | Fostamatinib | 90.3% | 9.7% | 96.74 |
| 24 | Axitinib | 90.0% | 10.0% | 93.23 |
| 25 | Apatinib | 89.6% | 10.4% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Tivozanib | 100.0% | 99.7% | +0.3% |
| Selpercatinib | 100.0% | 100.0% | +0.0% |
| Entrectinib | 100.0% | 99.6% | +0.4% |
| Pralsetinib | 100.0% | 100.0% | +0.0% |
| Alpelisib | 99.9% | 99.6% | +0.3% |
| Fedratinib | 99.9% | 99.9% | +0.0% |
| Nintedanib | 99.8% | 100.0% | -0.2% |
| Alectinib | 99.5% | 97.8% | +1.7% |
| Ponatinib | 99.4% | 100.0% | -0.6% |
| Lenvatinib | 99.3% | 98.8% | +0.4% |
| Gilteritinib | 98.8% | 100.0% | -1.2% |
| Tenalisib | 98.8% | 98.5% | +0.3% |
| Sorafenib | 97.9% | 94.0% | +3.9% |
| Sunitinib | 97.4% | 97.2% | +0.2% |
| Vandetanib | 97.3% | 98.6% | -1.2% |
| Repotrectinib | 97.0% | — | — |
| Brigatinib | 96.4% | 94.9% | +1.5% |
| Regorafenib | 96.3% | 98.7% | -2.4% |
| Futibatinib | 95.9% | 97.7% | -1.8% |
| Cabozantinib | 95.2% | 97.5% | -2.4% |
| Avapritinib | 93.6% | — | — |
| Erdafitinib | 93.0% | 94.7% | -1.7% |
| Fostamatinib | 90.3% | — | — |
| Axitinib | 90.0% | — | — |
| Apatinib | 89.6% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_breast | Breast | ref |
| BRCA-US | Breast | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.1ms